The U.S. Supreme Court's decision to strike down the federal government's ban on offensive trademark registrations in a case involving rock band The Slants highlights just how little the provision fit into the overall confusion-preventing goals of the Lanham Act — and probably doomed similar rules, experts say.
A federal judge has barred Mylan Laboratories Inc. from making a generic version of the antibiotic Levaquin until at least December 2010.
German chip designer Infineon Technologies has filed a motion to dismiss a patent infringement lawsuit brought by rival Rambus Inc., repeating allegations that Rambus destroyed evidence in its efforts to force the memory-chip industry to pay up to $3 billion in annual royalties.
South Korea’s high-tech industry, embroiled in increasing patent litigation across the strait with Japanese rivals, has formed a patent consortium to protect intellectual property rights for semiconductors and flat-panel displays.
In a stinging blow to the E.U., the World Trade Organization has ruled for the U.S. and Australia in a bitterly fought dispute over trademarks and geographic indications for products such as champagne, parma ham, rioja wine and Budweiser beer.
The U.S. Court of Appeals for the District of Columbia has rejected a challenge to drug maker Alpharma Inc.’s exclusive right to market a generic version of the Pfizer Inc. epilepsy drug Neurontin.
New York intellectual property specialist Fish & Neave has not been able to stem a wave of departures that started last year, despite the firm’s recent merger with Boston general-practice firm Ropes & Gray.
A software vendor that has rattled the world’s futures industry with threats of patent litigation has laid down its demands in an open letter to the industry.
Once again, European governments have failed to reach an agreement on legislation on software patents, a policy initiative with a tortuous history.
The U.S. Patent and Trademark Office will host an exploratory meeting in with its counterparts in Europe, Japan, Canada and Australia to build a common front in a growing conflict with developing nations at the World Intellectual Property Organization over patent-law harmonization.
A Luxembourg court has ruled that Microsoft Corp. will have to abide immediately by the E.U.’s antitrust ruling, rejecting the software company’s claims that the court’s decision tramples on its intellectual property rights.
U.S. drug maker Pfizer Inc has lost a drug trademark lawsuit it filed with the Beijing No.1 Intermediate People's Court at the end of September against China's State Administration for Industry and Commerce.
Computer peripheral maker Agilent Technologies Inc. has sued Taiwanese rival Elan Microelectronics Corp. for infringing patents for optical mouse sensor technology.
Three’s the charm for French drug maker Sanofi-Aventis, whose bid for a reissuance of the U.S. patent for best-selling anti-blood clotting drug Lovenox finally has won approval from the U.S. Patent and Trademark office.
A joint venture between General Motors and South Korea’s Daewoo has sued China's Chery Automobile Co. Ltd, accusing the auto maker of knocking off its car designs.
A federal judge in Virginia has dismissed a key claim in auto insurer Geico’s trademark infringement lawsuit against Google.
In a move certain to raise red flags, the company behind a wave of controversial patent lawsuits over streaming media and wireless internet technology has vastly expanded its patent portfolio.
A federal judge in Delaware has reversed the last remaining aspect of a $7.1 million jury verdict from October 2003 for patent infringement against several of the nation's largest umbilical-cord blood banks.
For Gibbons, Del Deo, the key to attracting the right intellectual property attorneys has been a steadfast focus on corporate America.
Venturing into what has been treacherous territory for plaintiffs, U.S. furniture maker Herman Miller Inc. has filed a lawsuit against an Italian rival over trade dress rights.
Canada’s Research in Motion is edging perilously close to an injunction against U.S. sales of its popular BlackBerry text messaging devices following a setback Tuesday at a U.S. appeals court.